Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06502145 · ClinicalTrials.gov registry record · Phase 1
Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome
A Phase 1 study of Myelodysplastic Syndromes, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06502145 is a Phase 1 study of Myelodysplastic Syndromes that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 12 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06502145, a Phase 1 study of Myelodysplastic Syndromes, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase I study with a primary objective of determining the recommended phase II dose of iadademstat with azacitidine in adult subjects with myelodysplastic syndrome (MDS).
Conditions Studied
Interventions
- DRUG Azacitidine Level -1
- DRUG Azacitidine Level 0
- DRUG Azacitidine Level 1
- DRUG Iadademstat Level -1
- DRUG Iadademstat Level 0
Study Locations (1)
Wisconsin
- Froedtert Hospital & the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-01-10 |
| Est. Completion | 2027-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06502145
The ClinicalTrials.gov registry entry for NCT06502145 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (96% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 5 interventions - of which Azacitidine Level -1 is the first listed.
NCT06502145 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06502145 about?
NCT06502145 is a clinical study titled "Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome". This is a phase I study with a primary objective of determining the recommended phase II dose of iadademstat with azacitidine in adult subjects with myelodysplastic syndrome (MDS).
What is the current status of trial NCT06502145?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-01-10. Estimated completion is 2027-10.
What conditions does trial NCT06502145 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes.
What interventions are being tested in trial NCT06502145?
The interventions under investigation include: Azacitidine Level -1 (DRUG), Azacitidine Level 0 (DRUG), Azacitidine Level 1 (DRUG), Iadademstat Level -1 (DRUG), Iadademstat Level 0 (DRUG).
Who is sponsoring clinical trial NCT06502145?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06502145 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
-
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
RECRUITING · Phase 1
-
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
RECRUITING · Phase 1
-
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.